ClinicalTrials.gg

Program

nirogacestat

Also written as “PF-03084014”, “Nirogacestat” and “Nirogacestat oral tablet”.

Its studies are mostly in Multiple Myeloma · Desmoid Tumors · Ovarian Neoplasms · Leukemia · Breast Neoplasms, led by 4 companies.

Furthest: phase 4, since Jul 31, 202516 company-led studies, 5 open or runningNext primary completion: May 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany62 open or runningphase 4since Jul 31, 2025Dec 17, 2018May 28, 2027phase 2 · NCT07170644
Pfizer60 open or runningphase 2since Apr 2, 2014Apr 6, 2009none ahead
GlaxoSmithKline33 open or runningphase 2since Jul 22, 2025Jul 22, 2025none ahead
Precision BioSciences10 open or runningphase 1since Nov 12, 2019Nov 12, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Apr 6, 2009.

  1. Jun 10, 2013Phase 1 study in Breast Cancer MetastaticPfizer · NCT01876251 · 30 enrolled · United States, Belgium, Italy and more
  2. Apr 2, 2014Phase 2 study in Pancreatic NeoplasmsPfizer · NCT02109445 · 3 enrolled · United States
  3. Nov 20, 2014Phase 2 study in Triple Negative Breast NeoplasmsPfizer · NCT02299635 · 19 enrolled · United States, Hungary, Italy and more
  4. Jun 2, 2015Phase 1 study in Advanced Solid TumorsPfizer · NCT02462707
  5. Dec 17, 2018Merck KGaA, Darmstadt, Germany's first study: phase 3 study in Desmoid TumorsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03785964 · 142 enrolled · United States, Belgium, Canada and more
  6. Nov 12, 2019Precision BioSciences's first study: phase 1 study in Multiple MyelomaNew to Precision BioSciencesPrecision BioSciences · NCT04171843 · 48 enrolled · United States
  7. Oct 8, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05090566 · 46 enrolled · United States, Canada
  8. Apr 13, 2022Phase 2 study in Granulosa cell tumor of the ovaryMerck KGaA, Darmstadt, Germany · NCT05348356 · 53 enrolled · United States, Canada, Poland
  9. Jul 22, 2025GlaxoSmithKline's first study: phase 2 study in Multiple MyelomaNew to GlaxoSmithKlineGlaxoSmithKline · NCT07084896 · 106 enrolled · United States, Australia, Canada and more
  10. Jul 31, 2025Phase 4 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07176689 · 50 planned · Belgium, Germany, Italy and more
  11. Jul 31, 2025Phase 2 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07170644 · 20 enrolled · Japan
  12. Aug 7, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07171619 · 24 enrolled · United States
  13. Aug 25, 20252 phase 2 studies in Multiple MyelomaGlaxoSmithKline · NCT07150104, NCT07150091
  14. Nov 19, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07259330 · 20 enrolled · Netherlands

Ahead

  1. May 28, 2027Primary completion: phase 2 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07170644
  2. Feb 26, 2031Primary completion: phase 4 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07176689

TargetBeta

“Gamma-secretase inhibitor; Gamma-secretase inhibitor”ChEMBL 37, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07259330Healthy · Netherlands1CompletedMerck KGaA, Darmstadt, GermanyMar 27, 202620
NCT07150104Multiple Myeloma · Brazil, Canada, France and more2Active, not recruitingGlaxoSmithKlineApr 17, 202514
NCT07150091Multiple Myeloma · United States, Brazil, Canada and more2Active, not recruitingGlaxoSmithKlineApr 17, 202520
NCT07171619Healthy · United States1CompletedMerck KGaA, Darmstadt, GermanyNov 10, 202524
NCT07176689Desmoid Tumors · Belgium, Germany, Italy and more4RecruitingMerck KGaA, Darmstadt, GermanyFeb 26, 203150
NCT07170644Desmoid Tumors · Japan2Active, not recruitingMerck KGaA, Darmstadt, GermanyMay 28, 202720
NCT07084896Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingGlaxoSmithKlineApr 17, 2025106
NCT05348356Granulosa cell tumor of the ovary · United States, Canada, Poland2CompletedMerck KGaA, Darmstadt, GermanyJul 8, 202553
NCT05090566Multiple Myeloma · United States, Canada2TerminatedPfizerFeb 13, 202546
NCT04171843Multiple Myeloma · United States1TerminatedPrecision BioSciencesOct 19, 202248
NCT03785964Desmoid Tumors · United States, Belgium, Canada and more3CompletedMerck KGaA, Darmstadt, GermanyApr 7, 2022142
NCT02462707Advanced Solid Tumors1WithdrawnPfizerJun 20160
NCT02299635Triple Negative Breast Neoplasms · United States, Hungary, Italy and more2TerminatedPfizerJan 14, 201619
NCT02109445Pancreatic Neoplasms · United States2TerminatedPfizerNov 6, 20143
NCT01876251Breast Cancer Metastatic · United States, Belgium, Italy and more1TerminatedPfizerDec 24, 201530
NCT00878189Neoplasms by Histologic Type · United States, Italy1CompletedPfizerJan 10, 201372

How it is read

Names in the registry

  • “PF-03084014”, 10 entries
  • “Nirogacestat”, 7 entries
  • “Nirogacestat oral tablet”, 2 entries
  • “Nirogacestat and Famotidine”, 1 entry
  • “Nirogacestat and Rabeprazole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.